Moreover, this relationship was also evident in the setting of clinical trials where TIGIT+KLRG1+ TEX selectively increased in individuals carrying RA HLA risk alleles but not in carriers of non-risk alleles after treatment with abatacept (CTLA4Ig). The gene discussed is TEX46; the disease is rheumatoid arthritis.